H

Hugel Inc
KOSDAQ:145020

Watchlist Manager
Hugel Inc
KOSDAQ:145020
Watchlist
Price: 227 000 KRW -1.09% Market Closed
Market Cap: 2.8T KRW

Hugel Inc's latest stock split occurred on Jul 8, 2020

The company executed a 959692-for-319897 stock split, meaning that for every 319897 shares held, investors received 959692 new shares.

Before the split, Hugel Inc traded at 173599.9894 per share. Afterward, the share price was about 176700.

The adjusted shares began trading on Jul 8, 2020. This was the only stock split in Hugel Inc's history.

Last Splits:
Jul 8, 2020
959692-for-319897
Pre-Split Price
173 599.9894 173 599.9894
Post-Split Price
176 700
Before
After
Last Splits:
Jul 8, 2020
959692-for-319897

Hugel Inc
Stock Splits History

Hugel Inc Stock Splits Timeline
Jul 8, 2020
Jul 8, 2020
Split 959692-for-319897
x3.0000031260062
Pre-Split Price
173 599.9894 173 599.9894
Post-Split Price
176 700
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.14 0.14 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.5 8.5 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Jan 6, 2026
Itochu Corp
F:IOC0
10-for-1
x10
1060 106 EUR N/A
Load More

Hugel Inc
Glance View

Market Cap
2.8T KRW
Industry
Biotechnology

In the bustling landscape of the global biopharmaceutical market, Hugel Inc. stands out as a formidable player rooted in the dynamic world of aesthetics and medical treatments. Established in South Korea, Hugel Inc. embarked on its journey with a focus on producing botulinum toxin products, a niche that has rapidly expanded due to a surge in demand for non-surgical cosmetic procedures. The company navigated early challenges with innovative prowess, crafting a strong reputation for high-quality products that cater to a global clientele. The ethos of innovation and safety permeates its operations, enabling Hugel to diversify its portfolio and steadily gain traction in international markets, including significant footprints in Asia, Europe, and Latin America. Through a network of strategic partnerships and a robust distribution channel, Hugel not only pioneered advancements in cosmetic treatments but also cemented its status as a key contributor to the evolving aesthetics industry. The company's revenue model hinges upon the development, production, and distribution of its botulinum toxin and hyaluronic acid-based products. By focusing on research and development, Hugel enhances its capacity to innovate, delivering cutting-edge solutions that meet the rising demands of beauty-conscious consumers. Its business strategy also extends to therapeutics, exploring potential applications of its core products to address various medical conditions. Hugel's financial growth is propelled by the continuous expansion into new geographical territories and the gradual introduction of new, clinically-researched products. As the company continues to navigate the intricate regulatory landscapes of the pharmaceutical industry, it maintains an unwavering commitment to quality, ensuring that each product meets rigorous safety standards while catering to the evolving desires of its diverse customer base worldwide.

Intrinsic Value
300 622.21 KRW
Undervaluation 24%
Intrinsic Value
Price
H
Back to Top